Ikerian’s Post

Saturday was #NationalFamilyHistoryDay, and it’s a great reminder of how our family health history shapes our understanding of our own health. From genetic conditions to inherited cancer risks, knowing the medical histories of our relatives gives us vital insights that can help prevent, diagnose, and treat diseases.   In precision medicine, this is where it gets exciting. By combining family history with genomics and clinical data (and environmental data - like the fireplace below), we can offer more personalized care tailored to each person’s unique genetic makeup. This approach is changing how we think about disease risks and helping us develop treatments that are both more targeted and effective. At Velsera, we’re bridging the gap between family health history and advanced genomic data, making it actionable for both patients and clinicians. It’s innovations like these that will lead to better outcomes and give patients more control over their health.   Take a moment today to think about your family’s health history—it might be the key to unlocking better care for you & future generations.

Exciting advancements in ALS research! 🧬 Our latest blog explores cutting-edge efforts to identify new drug targets for ALS treatment presented at our Annual Meeting. 🌟 Discover how scientists are using tools like artificial intelligence to pinpoint specific targets and exploring other avenues of study like the immune system. This research is a crucial step toward developing treatments that can slow or halt ALS progression, bringing us closer to effectively managing this devastating disease. 💡 Learn about collaborations between supporting scientists and institutions driving this progress and how Target ALS is supporting these efforts. Together, we can realize our vision of a world where #EveryoneLives. 👉 Read the full blog: https://bit.ly/4cZ8uRr #ALSResearch #ALS #MedicalInnovation #DrugDiscovery

Final reminder: Join Dr. Laia Montoliu Gaya from the University of Gothenburg tomorrow to explore how Simoa® assays are transforming Alzheimer’s disease diagnosis and staging, helping make progress more accessible to all. Discover the latest advances in assay development, technical innovations, and impactful strategies shaping the field. 🔗 Register here: https://lnkd.in/eR2nBEjV #Alzheimers #AlzheimersDisease #Diagnostics #Assays #Webinar #SelectScienceWebinars Quanterix

Join Dr. Laia Montoliu Gaya from the University of Gothenburg on Nov 14 to explore how Simoa® assays are transforming Alzheimer’s disease diagnosis and staging, helping make progress more accessible to all. Discover the latest advances in assay development, technical innovations, and impactful strategies shaping the field. 🔗 Register here: https://lnkd.in/e6zJQiz9 #Alzheimers #AlzheimersDisease #Diagnostics #Assays #Webinar #SelectScienceWebinars Quanterix

Join Dr. Laia Montoliu Gaya from the University of Gothenburg on Nov 14 to explore how Simoa® assays are transforming Alzheimer’s disease diagnosis and staging, helping make progress more accessible to all. Discover the latest advances in assay development, technical innovations, and impactful strategies shaping the field. 🔗 Register here: https://lnkd.in/e2QTDBMD #Alzheimers #AlzheimersDisease #Diagnostics #Assays #Webinar #SelectScienceWebinars Quanterix

🚀 Excited to be speaking today at the Monogenic Inflammatory Bowel Disease workshop at St Anne's College, University of Oxford! 🎓 I’ll be presenting on the "Application of Artificial Intelligence to Diagnose Monogenic Inflammatory Bowel Disease in Primary Care," 🤖 where I’ll dive into how AI could boost diagnostic accuracy and streamline clinical decision-making for monogenic IBD. 🧬 At Mendelian, we’re leveraging #AI-powered tools to reduce diagnostic delays in rare diseases like mIBD. Our clinical decision support tool, MendelScan, is designed to enable earlier diagnoses and optimise healthcare resource allocation, driving more efficient and personalised care for patients. 💡 Excited to share insights and learn from the incredible experts in this field! #IBD #MonogenicIBD #ClinicalGenomics #ArtificialIntelligence #PrecisionMedicine #RareDisease #HealthcareInnovation #Workshop

🌟 Exciting News! 🌟 On May 28th in Florence, Italy, during the AFFIRMO project meeting, we launched a new collaborative cluster focused on cardiac disease and multimorbidity management! 💖🔬 The @Horizon Europe projects AFFIRMO, ARISTOTELES EU Project, and TARGET EU Project have come together to enhance research, share insights, and innovate for better patient outcomes. This cluster is set to revolutionize how we approach atrial fibrillation (AF) and its comorbidities by leveraging AI, personalized care models, and a holistic approach to patient management. We’re thrilled about the potential of this collaboration and can’t wait to see the amazing advancements it will bring! 🚀💡 Discover more on our website! 🌍✨ https://lnkd.in/ddjhjFT2 #CardiacHealth #Multimorbidity #AIInHealthcare #HorizonEurope #AFFIRMO #ARISTOTELES #TARGET #MedicalInnovation #HealthcareRevolution #ResearchCollaboration #AtrialFibrillation #HeartHealth

Thanks MIT School of Engineering for covering my research!

🧬 Discovering your family’s health history can reveal vital insights for improved well-being. That's why the Collaborative's Family Health History (FHH) Flagship Project is placing itself at the forefront of this journey, driving progress with fresh publications, global partnerships, and cutting-edge methods in personalized care. Dive in to see their achievements and find out how you can get involved! https://lnkd.in/gWcajhSM #Genomics #GenomicMedicine #FamilyHealth #PersonalizedMedicine

#DYK The #HeartFlowAnalysis helps physicians determine which patients need to go to the cath lab for an invasive assessment while appropriately avoiding the cath lab for patients without blood-flow limiting disease. Learn more about our technology and clinical research: https://bit.ly/45KgDoK. #FFRCT #CCTA #heartcare #AI #yesCCT